Best Peptides for Gut Health

Gastrointestinal dysfunction is one of the most common and most underestimated drivers of systemic health problems. The gut mucosal barrier, when intact and healthy, performs a remarkable feat: it absorbs nutrients selectively while keeping the trillions of bacteria in the intestinal lumen from crossing into the bloodstream. When this barrier breaks down, whether through chronic inflammation, autoimmune activity, dietary insults, or frank ulceration, the consequences extend well beyond the gut itself. Systemic immune activation, nutritional malabsorption, the microbiome-gut-brain axis disruption, and the chronic fatigue associated with long-standing IBD all trace back to compromised intestinal integrity.

Peptide research has produced a small but genuinely compelling set of compounds with evidence for GI applications. The most relevant work involves three overlapping mechanisms: structural mucosal repair and angiogenesis, anti-inflammatory signaling at the epithelial level, and collagen deposition for barrier restoration. The compounds covered in this guide each engage one or more of these mechanisms, and the best-evidenced options address multiple simultaneously.

What distinguishes gut health peptides from most other peptide applications is administration route flexibility. Several compounds covered here can be taken orally, which is unusual in the peptide world. Most peptides are rapidly degraded by the proteolytic enzymes of the gastrointestinal tract before they can exert systemic effects. BPC-157 is a striking exception due to its structural stability in gastric acid. KPV is another, due to its active transport into intestinal cells via the PepT1 transporter rather than passive absorption. This oral viability makes gut peptides more accessible and logistically simpler than most injectable-only compounds.

Critical caveat: No peptide in this guide is FDA-approved for any gastrointestinal indication. The evidence base is predominantly preclinical, with very limited human clinical data for BPC-157, and no human clinical trial data at all for KPV in IBD contexts. These compounds are experimental and should be considered only under physician supervision, never as a replacement for proven IBD therapies or as a way to delay medical evaluation of serious gastrointestinal symptoms.

How We Ranked These Peptides

Gut health rankings weigh:

1. GI-specific evidence volume. How many studies exist specifically examining this compound in gastrointestinal contexts, across what range of conditions and animal models?
2. Mechanistic relevance. Does the compound's documented mechanism directly engage intestinal repair, mucosal integrity, tight junction function, or inflammatory regulation in gut tissue?
3. Oral administration viability. For GI applications, oral delivery that reaches the gut mucosa before systemic absorption is often preferable to injectable systemic delivery.
4. Evidence quality and independence. Human data outweighs animal data; independent replication outweighs single-lab findings.

1. BPC-157, Best Overall for Gastrointestinal Healing

BPC-157 earns the top position in this category by a wide margin. Its origin as a gastric-derived peptide, its exceptional stability in the acidic GI environment, its oral administration viability, and its breadth of published GI research across multiple conditions and animal models make it the most comprehensively supported gut healing peptide available.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15-amino acid sequence) derived from a protective protein found in human gastric juice, where it functions to maintain mucosal integrity and promote gastrointestinal homeostasis. The synthetic version used in research is a stable fragment of this naturally occurring compound. Its derivation from a GI-protective protein is not coincidental: the compound was effectively reverse-engineered from the body's own gut-protective system.

Gastric Acid Stability and Oral Administration

The most practically important property of BPC-157 for gut health applications is its remarkable stability in gastric acid. Unlike virtually all other therapeutic peptides, which are denatured and fragmented by pepsin and the low pH of the gastric environment within minutes, BPC-157 retains its structural integrity and biological activity after passage through the stomach.

This stability makes oral administration a viable route specifically for gastrointestinal applications. When taken orally, BPC-157 can act directly on the gastric and intestinal mucosa it contacts before reaching systemic circulation. This means the therapeutic concentration is delivered precisely where it is needed: the inflamed, ulcerated, or damaged mucosal surface. This is particularly relevant for upper GI conditions (gastric ulcers, esophageal inflammation) and for lower GI conditions when BPC-157 reaches the colon without complete proximal absorption.

The caveat is important: while BPC-157 can transit the GI tract intact, it is unclear how much reaches inflamed sites in the distal colon versus how much is absorbed proximally. For distal colonic conditions specifically, subcutaneous injection providing systemic delivery may be more reliable. For upper GI and small intestinal applications, oral delivery is mechanistically appropriate.

Mechanisms in GI Tissue

BPC-157's GI mechanisms are multi-layered and consistently demonstrated across published research:

Angiogenesis and VEGF upregulation. BPC-157 stimulates vascular endothelial growth factor (VEGF) expression, promoting the formation of new blood vessels in healing tissue. Adequate blood supply is essential for mucosal repair; inflamed and ulcerated tissue often has compromised vascularity that limits healing. By driving angiogenesis, BPC-157 restores the oxygen and nutrient delivery that regenerating mucosal cells require.

Nitric oxide system modulation. BPC-157 upregulates nitric oxide synthase (NOS) and increases nitric oxide (NO) production, producing vasodilation and improved blood flow to injured tissue. The NO pathway is a central mediator of BPC-157's gastrointestinal cytoprotection, and experimental blockade of NOS attenuates many of BPC-157's gut-healing effects.

Growth factor signaling. BPC-157 activates ERK1/2 and the FAK-paxillin pathway, promoting cell survival, migration, and proliferation in injured mucosal tissue. It also upregulates growth hormone receptor expression in gastrointestinal cells, enhancing local responsiveness to GH, which plays a role in gut mucosal maintenance.

Anti-inflammatory effects. BPC-157 reduces COX-2 expression, myeloperoxidase activity, and pro-inflammatory cytokines including IL-6 and TNF-alpha in animal models of GI inflammation. This reduces the inflammatory burden on healing tissue without the broad immunosuppression that makes corticosteroids problematic for long-term use.

Gastrointestinal Research Evidence

Preclinical data for BPC-157 in GI contexts is the most extensive in this guide:

Gastric ulcer healing. Multiple studies in rat models of gastric ulceration demonstrate that BPC-157 accelerates ulcer healing, reduces inflammatory infiltrates, and restores mucosal architecture significantly faster than controls. The healing effect is observed across both acutely induced (ethanol, indomethacin) and chronically maintained ulcer models.

Intestinal inflammation. In models of IBD, BPC-157 reduces colonic inflammation, restores intestinal motility, and attenuates the immune cell infiltration and cytokine storm characteristic of active colitis. Oral and injectable administration routes have both shown efficacy in preclinical IBD models.

Gut motility. A Phase II proof-of-concept clinical study found that ipamorelin (a different peptide) accelerated return of bowel function following abdominal surgery. For BPC-157 specifically, preclinical work documents normalization of intestinal motility in models of pharmacologically induced dysmotility. A registered Phase 1 safety trial (NCT02637284) exists but its results have not been fully published.

Fistula healing. BPC-157 has demonstrated efficacy in healing various types of fistulas in animal models, including gastrointestinal fistulas. This is mechanistically relevant for Crohn's disease, where perianal and enterocutaneous fistulas are a major source of morbidity.

Best for: Gastric ulcers, esophageal inflammation, inflammatory bowel disease (as adjunctive support), intestinal permeability, post-antibiotic gut dysbiosis recovery, general mucosal healing after injury or surgery. Also relevant when gut health problems may be contributing to systemic symptoms through the gut-brain or gut-immune axes.

Typical dosage:

• Oral for GI applications: 250 to 500 mcg daily, in capsule or dissolved in water, taken on an empty stomach
• Subcutaneous injection for combined GI + systemic effects: 250 to 500 mcg daily near the abdomen
• Cycle length: 4 to 8 weeks, then 2 to 4 weeks off

Limitations: As of early 2026, essentially no randomized controlled trial data exists in humans. The single Phase 1 trial remains unpublished. BPC-157 is a WADA-prohibited substance and is FDA Category 2 (meaning compounding pharmacies cannot produce it). Oral bioavailability for distal colonic conditions may be limited compared to the proximal GI tract.

2. KPV, Best for Inflammatory Bowel Conditions

KPV earns the second position through a distinct and elegantly targeted mechanism: it inhibits NF-kB inflammatory signaling specifically within inflamed intestinal tissue through the PepT1 transporter system, a natural targeting mechanism that effectively concentrates KPV's anti-inflammatory activity where it is most needed.

KPV (Lys-Pro-Val) is a tripeptide derived from positions 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH). At just three amino acids, it is among the smallest biologically active peptides in clinical discussion. Despite this simplicity, it retains the full anti-inflammatory activity of alpha-MSH while lacking its pigmentation effects, because its mechanism bypasses melanocortin receptors entirely.

NF-kB Inhibition: The Master Inflammatory Switch

The primary mechanism by which KPV exerts its anti-inflammatory effects is through inhibition of nuclear factor-kappa B (NF-kB), one of the most important transcription factors in inflammatory biology. NF-kB controls the expression of hundreds of inflammation-related genes, including TNF-alpha, IL-1beta, IL-6, IL-8, COX-2, and dozens of adhesion molecules and chemokines that drive the inflammatory cascade.

Under normal resting conditions, NF-kB is held inactive in the cytoplasm by its inhibitor protein IkB-alpha. When inflammatory signals arrive (bacterial products, cytokines, reactive oxygen species), IkB-alpha is phosphorylated and degraded, releasing NF-kB to translocate to the nucleus and activate inflammatory gene transcription. KPV interrupts this process by stabilizing IkB-alpha and blocking the nuclear translocation of the p65/RelA NF-kB subunit through competitive interference with the importin-alpha3 transport mechanism.

This is a pharmacologically elegant intervention. Rather than broadly suppressing immune function (as corticosteroids do by affecting multiple signaling pathways simultaneously), KPV acts at a specific checkpoint in the NF-kB activation cascade. The result is selective attenuation of NF-kB-driven inflammatory gene expression without the broad immunosuppression that makes chronic corticosteroid use problematic.

The PepT1 Mechanism: Natural Targeting to Inflamed Gut

The most therapeutically significant aspect of KPV's pharmacology for gut health is its interaction with PepT1 (SLC15A1), the intestinal di/tripeptide transporter.

PepT1 is normally expressed at high levels in the small intestine, where it absorbs dietary di- and tripeptides from the gut lumen. In healthy colon, PepT1 expression is low. However, during inflammatory bowel disease, PepT1 expression is dramatically upregulated in the colon, the inflamed tissue. This is the key insight: KPV, as a tripeptide, is a perfect substrate for PepT1. In an IBD patient, PepT1 overexpression in the inflamed colon actively pulls KPV out of the gut lumen and into the intestinal epithelial cells and colonic immune cells that are driving the inflammation.

The landmark 2008 Gastroenterology study by Dalmasso and colleagues demonstrated this mechanism directly. KPV was shown to be actively transported into colonic epithelial cells and immune cells via PepT1, where it reduced NF-kB and MAPK signaling, suppressed pro-inflammatory cytokine production, and attenuated disease severity in both DSS-induced and TNBS-induced colitis mouse models. Crucially, when PepT1 knockout mice were used (animals lacking the transporter), KPV produced no anti-inflammatory or anti-tumorigenic effects whatsoever. The therapeutic effect is entirely PepT1-dependent.

This means KPV, when taken orally, is preferentially absorbed by inflamed colon rather than healthy colon. Healthy intestinal tissue does not significantly take up KPV because PepT1 is not upregulated there. This natural targeting mechanism is highly desirable pharmacologically: maximum drug delivery to the pathological tissue, minimal unnecessary systemic exposure.

GI Research Evidence

Ulcerative colitis. In multiple mouse models of chemically induced colitis (DSS, TNBS), oral KPV significantly reduced disease severity scores, colonic tissue damage, histological inflammatory scores, and pro-inflammatory cytokine expression. The results were consistent across models and laboratories.

Colitis-associated cancer. A 2016 study in Cellular and Molecular Gastroenterology and Hepatology demonstrated that KPV dramatically reduced colonic tumorigenesis in a mouse model of colitis-associated colorectal cancer. Tumor numbers, sizes, and overall tumor burden were significantly decreased. This anti-tumorigenic effect was abolished in PepT1-knockout mice, confirming that the mechanism requires PepT1-mediated uptake. While this finding has not been evaluated in humans, it suggests KPV may have relevance to the increased colorectal cancer risk associated with long-standing inflammatory bowel disease.

Nanoparticle-enhanced delivery. A 2017 study developed hyaluronic acid-functionalized nanoparticles for oral KPV delivery. The nanoparticle formulation achieved therapeutic efficacy at dramatically lower concentrations than free KPV, while simultaneously accelerating mucosal healing in a mouse ulcerative colitis model. This represents a potential next-generation delivery strategy that may eventually reach clinical development.

Best for: Inflammatory bowel disease (ulcerative colitis, Crohn's colitis), intestinal barrier dysfunction driven by inflammatory mechanisms, gut conditions where NF-kB-mediated inflammation is the primary driver, stacking with BPC-157 for complementary anti-inflammatory and structural repair effects.

Typical dosage:

• Oral for GI applications: 500 to 1,500 mcg per day, in one or two divided doses
• Subcutaneous for systemic anti-inflammatory effects: 200 to 500 mcg per day
• Oral is preferred for IBD/colitis applications due to PepT1-mediated intestinal targeting
• Cycle length: 4 to 8 weeks

Limitations: No human clinical trials have been completed for KPV in any GI indication. All evidence is preclinical. The PepT1 targeting mechanism means KPV's oral GI effects are dependent on having IBD-like PepT1 upregulation in the colon; this mechanism is less relevant for upper GI conditions (gastric ulcers, esophageal inflammation) where BPC-157 is more directly applicable. As of early 2026, KPV is under regulatory review that may permit licensed compounding pharmacies to prepare it with a physician's prescription following HHS announcements, but this reclassification has not been formalized.

3. GHK-Cu, Best for Mucosal Healing and Collagen Restoration

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) occupies an unusual position in the gut health peptide landscape. It is primarily researched for skin and wound healing applications, where it has actual human clinical evidence. Its GI relevance is mechanistically credible but less directly studied than BPC-157 or KPV.

GHK-Cu is a naturally occurring tripeptide copper complex found in human plasma, saliva, and urine. Plasma levels decline with age, from approximately 200 ng/mL at age 20 to approximately 80 ng/mL at age 60, a trajectory that correlates with declining wound healing and tissue maintenance capacity. It is most famous in the aesthetics world for its ability to stimulate collagen synthesis and promote skin regeneration, demonstrated in multiple human clinical trials.

The gut mucosal healing relevance follows from these same mechanisms. The intestinal mucosa is a rapidly renewing tissue that requires constant collagen deposition for structural integrity. GHK-Cu stimulates fibroblast proliferation and collagen synthesis in wound healing contexts. In clinical trials for non-GI wounds, including diabetic ulcers and Mohs surgical wounds, GHK-Cu demonstrated significantly improved re-epithelialization. These same healing mechanisms apply to mucosal surfaces, including the intestinal epithelium.

GHK-Cu also modulates over 4,000 human genes as revealed by gene chip analysis, including genes involved in wound healing, anti-inflammatory signaling, antioxidant defense, and tissue remodeling. This broad transcriptional effect reflects GHK-Cu's interaction with copper-responsive regulatory elements in gene promoter regions.

For gut health specifically, GHK-Cu's most relevant properties are mucosal collagen synthesis support, angiogenic promotion through nerve and blood vessel outgrowth stimulation, and the anti-inflammatory dimension of its gene regulation profile. It is most appropriately used as a supportive addition to a BPC-157 and KPV core protocol rather than as a standalone gut healing agent.

Best for: Supporting mucosal collagen integrity alongside BPC-157-driven structural repair. Leaky gut with a connective tissue component. Post-endoscopic or surgical healing of GI tissue. Individuals who want the gut health and skin/aesthetics benefits of GHK-Cu simultaneously.

Typical dosage:

• Subcutaneous: 1 to 2 mg, 2 to 3 times per week
• Short plasma half-life (approximately 30 minutes) limits systemic effectiveness; higher injection frequency is more effective than higher individual doses
• Topical application is not relevant for GI conditions
• Note: GHK-Cu is not typically taken orally as the copper complex may not survive GI transit in its intact bioactive form

Limitations: GHK-Cu's strongest human clinical evidence is topical and dermatological. GI-specific research is largely mechanistic inference from its wound healing properties rather than direct intestinal research. The copper component requires consideration of total copper intake, particularly with prolonged injectable use. Unlike BPC-157 and KPV, oral administration is not an established route for GHK-Cu GI applications.

Larazotide: The Emerging Tight Junction Modulator (Clinical Trials)

Any comprehensive gut health guide must address Larazotide acetate (AT-1001), a synthetic octapeptide that directly targets intestinal tight junctions. It represents a fundamentally different approach from the three compounds ranked above.

Larazotide works by directly preventing the opening of tight junctions between intestinal epithelial cells. Tight junctions, formed by proteins including claudins, occludins, and zonula occludens proteins, are the primary gatekeepers of intestinal permeability. When tight junctions open inappropriately (triggered by gliadin in celiac disease, by cytokines in IBD, by dysbiotic bacterial products, or by other insults), the gut barrier becomes permeable to antigens that should remain in the lumen.

Larazotide has been evaluated in multiple Phase 2 clinical trials in celiac disease patients, where it reduced intestinal permeability, decreased gastrointestinal symptoms, and attenuated the immune activation triggered by gluten challenge. This is direct clinical evidence of a peptide modulating tight junction function in humans.

However, Peptidepedia does not yet have a full Larazotide article. The compound remains investigational and has not received FDA approval. Its commercial supply chain as a research compound is not as established as BPC-157 or KPV. Until we can provide the depth of analysis we apply to our full peptide guides, including complete mechanism review, dosing protocols, safety data, and legal status, we are including Larazotide here as an important concept for readers to be aware of when researching leaky gut, without recommending specific dosing or sourcing guidance.

The BPC-157 + KPV Core Stack for Gut Health

The most evidence-supported combination for gut healing pairs BPC-157 with KPV. These two peptides work through entirely non-overlapping mechanisms and address the two primary components of intestinal dysfunction simultaneously: structural damage and inflammatory signaling.

BPC-157 drives structural repair at the tissue level: it promotes angiogenesis to restore blood supply, upregulates growth factor signaling to stimulate cell proliferation and migration, and reduces acute inflammatory cytokines. KPV addresses the inflammatory cascade at the cellular signaling level: it inhibits NF-kB nuclear translocation, suppresses the transcriptional output of inflammatory genes, and via PepT1 delivers this inhibition specifically to the inflamed intestinal cells that are perpetuating the damage.

Together, BPC-157 creates a favorable tissue environment for healing while KPV reduces the inflammatory stimulus that is driving tissue destruction. For IBD specifically, this combination addresses both the structural mucosal deficit and the immune dysregulation that prevents natural repair.

Combined oral protocol for GI applications:

• BPC-157: 250 to 500 mcg orally, once daily, on an empty stomach
• KPV: 500 to 1,000 mcg orally, once or twice daily
• Cycle: 6 to 8 weeks of both compounds simultaneously, then 4 weeks off
• Both can be taken in the same oral dose, dissolved in water or in capsule form

Adding GHK-Cu (advanced stack):

• GHK-Cu: 1 mg subcutaneously, 2 to 3 times per week
• Provides collagen and mucosal integrity support while BPC-157 and KPV drive repair and inflammation control

Safety and Legal Considerations

Regulatory status. No peptide in this guide is FDA-approved for any gastrointestinal indication. BPC-157 was designated as a Category 2 bulk drug substance in 2023, restricting its use in compounding pharmacies. KPV is under regulatory review that may result in reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it with a physician's prescription; this reclassification had not been finalized as of this writing. GHK-Cu has more favorable compounding status. BPC-157 is explicitly prohibited by WADA, the UFC, the NFL, and several other major sports organizations since 2022.

Known safety considerations by peptide:

• BPC-157: No acute toxicity in animal studies across a wide dose range. Only one incomplete Phase 1 human trial. Theoretical immunogenicity concern identified by the FDA. Sourcing from unregulated suppliers introduces contamination risk separate from the compound's intrinsic safety profile.
• KPV: Favorable preclinical safety profile. Does not appear to broadly suppress immune function unlike corticosteroids. No human clinical trial safety data exists. Mild GI discomfort has been anecdotally reported.
• GHK-Cu: Well-tolerated topically in human clinical trials. The copper component warrants attention with prolonged injectable use; excessive copper accumulation is a theoretical concern with very long-term high-dose protocols. Not DEA-scheduled.

Monitoring recommendations. Anyone using these compounds for active GI conditions should maintain physician supervision and appropriate monitoring:

• Baseline and follow-up endoscopic or imaging assessment for IBD patients
• Calprotectin (fecal marker of intestinal inflammation) as a trackable biomarker
• Standard metabolic panel to monitor hepatic and renal function
• CRP and ESR for inflammatory monitoring

Drug interaction caution. These peptides are not formally studied for interactions with immunosuppressive IBD therapies (biologics, azathioprine, mesalazine). Anyone on standard IBD pharmacotherapy should discuss peptide co-administration explicitly with their gastroenterologist before proceeding.

Conclusion

BPC-157 leads the gut health peptide field by a clear margin. Its gastric acid stability enables oral administration directly to the mucosal surfaces it heals. Its mechanisms span angiogenesis, growth factor signaling, nitric oxide modulation, and anti-inflammatory cytokine reduction. Its preclinical evidence volume in GI-specific contexts is unmatched among research peptides.

KPV occupies a genuinely unique therapeutic niche through its PepT1-mediated natural targeting to inflamed intestinal tissue. The NF-kB inhibition mechanism is one of the most mechanistically direct anti-inflammatory approaches available, and the PepT1 delivery system makes oral administration not just viable but preferable for IBD applications. The BPC-157 and KPV combination, taken orally, is the most evidence-supported gut health peptide stack for conditions driven by both mucosal damage and intestinal inflammation.

GHK-Cu adds mucosal collagen support and broad regenerative gene expression modulation, most valuable as a complementary addition to the core stack.

The honest accounting of the evidence: while these mechanisms are compelling and the animal data is genuinely encouraging, the absence of human randomized controlled trials for all three compounds means that anyone using them for serious GI conditions should do so as a complement to evidence-based medical care, not as a replacement for it. Physicians, gastroenterologists specifically, should be involved in the decision to add any of these peptides to an existing treatment plan.